INFANRIX HEXA

국가: 인도네시아

언어: 인도네시아어

출처: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Download 제품 특성 요약 (SPC)
05-06-2023

유효 성분:

DIPHTERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, FILAMENTOUS HAEMAGGLUTININ, PERTACTIN, HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID, HEPATITIS B SURFACE ANTIGEN, INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY STRAIN), INA

제공처:

GLAXO WELLCOME INDONESIA - Indonesia

INN (국제 이름):

DIPHTERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, FILAMENTOUS HAEMAGGLUTININ, PERTACTIN, HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID, HEPATITIS B SURFACE ANTIGEN, INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY STRAIN), INA

복용량:

NOT LESS THAN 30 IU /NOT LESS THAN 40 IU /25 MCG /25 MCG /8 MCG /10 PRP AND ~ 25 T MCG /10 MCG /40

약제 형태:

SERBUK DAN SUSPENSI INJEKSI

패키지 단위:

DUS, 1 PRE-FILLED SYRINGE @ 0,5 ML + 1 VIAL @ 0,5 ML

Manufactured by:

GlaxoSmithKline Biologicals SA - Belgium

승인 날짜:

2021-12-23

제품 특성 요약

                                FAW_leaINFHEXinj_ PI update GDS22 IPI17 (One PFS)_circ1_14Nov22 –
for submission
_Page 1 of 10_
INFANRIX HEXA
DIPHTHERIA (D), TETANUS (T), PERTUSSIS (ACELLULAR, COMPONENT) (PA),
HEPATITIS B (RDNA)
(HBV), POLIOMYELITIS (INACTIVATED) (IPV) AND _HAEMOPHILUS INFLUENZAE_
TYPE B VACCINE
(ADSORBED)
POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION
QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, 1 dose (0.5 mL) contains:
Diphtheria toxoid
1
not less than 30 International Units (IU)
Tetanus toxoid
1
not less than 40 International Units (IU)
_Bordetella pertussis_ antigens
Pertussis toxoid (PT)
1
25 micrograms
Filamentous Haemagglutinin (FHA)
1
25 micrograms
Pertactin (PRN)
1
8 micrograms
Hepatitis B surface antigen (HBs)
2,3
10 micrograms
Poliovirus (inactivated) (IPV)
type 1 (Mahoney strain)
4
40 D-antigen unit
type 2 (MEF-1 strain)
4
8 D-antigen unit
type 3 (Saukett strain)
4
32 D-antigen unit
_Haemophilus influenzae_ type b polysaccharide
10 micrograms
(polyribosylribitol phosphate, PRP)
3
conjugated to tetanus toxoid as carrier protein
approximately 25 micrograms
1
adsorbed on aluminium hydroxide, hydrated (Al(OH)
3
)
0.5 milligrams Al
3+
2
produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
3
adsorbed on aluminium phosphate (AlPO
4
)
0.32 milligrams Al
3+
4
propagated in VERO cells
The DTPa-HBV-IPV component is presented as a turbid white suspension.
Upon storage, a white deposit
and clear supernatant can be observed. This is a normal observation.
The Hib component is presented as a white powder.
For excipients, see _List of Excipients_.
CLINICAL INFORMATION
INDICATIONS
_INFANRIX HEXA_ is indicated for primary vaccination of infants and
booster vaccination of toddlers against
diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and
_Haemophilus influenzae_ type b.
The use of _INFANRIX HEXA_ should be in accordance with official
recommendations.
DOSAGE AND ADMINISTRATION
POSOLOGY
The primary vaccination schedule consists of two or three doses (of
0.5 mL) which sho
                                
                                전체 문서 읽기
                                
                            

문서 기록보기